Joshua J DeClercq
Overview
Explore the profile of Joshua J DeClercq including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lin Y, DeClercq J, Ayers G, Gilmor R, Collett G, Jain N
J Clin Med
. 2024 Jan;
13(1).
PMID: 38202167
Total hip arthroplasty (THA) has become a growing treatment procedure for debilitating hip pathologies. Patients experienced post-operative complications and revision surgeries according to large THA registries. To fully understand the...
2.
Thakur B, Ayers G, Atem F, DeClercq J, Jain N
Am J Phys Med Rehabil
. 2023 Mar;
102(10):855-860.
PMID: 36882301
Abstract: Well-designed randomized controlled clinical trials assessing treatments in the field of physical medicine and rehabilitation are essential for evidence-based patient care. However, there are challenges unique to clinical trials...
3.
Leslie G, Wang J, Richardson M, Haggarty B, Hua K, Duong J, et al.
PLoS Pathog
. 2016 Nov;
12(11):e1005983.
PMID: 27855210
HIV-1 entry can be inhibited by soluble peptides from the gp41 heptad repeat-2 (HR2) domain that interfere with formation of the 6-helix bundle during fusion. Inhibition has also been seen...
4.
Wang J, Exline C, DeClercq J, Llewellyn G, Hayward S, Li P, et al.
Nat Biotechnol
. 2015 Nov;
33(12):1256-1263.
PMID: 26551060
Genome editing with targeted nucleases and DNA donor templates homologous to the break site has proven challenging in human hematopoietic stem and progenitor cells (HSPCs), and particularly in the most...
5.
Wang J, DeClercq J, Hayward S, Li P, Shivak D, Gregory P, et al.
Nucleic Acids Res
. 2015 Nov;
44(3):e30.
PMID: 26527725
The adoptive transfer of engineered T cells for the treatment of cancer, autoimmunity, and infectious disease is a rapidly growing field that has shown great promise in recent clinical trials....